The immunosuppressive activity of daunomycin on the production of spleen plaque-forming cells was determined in mice treated with the antibiotic and later challenged with sheep erythrocytes. The immune response was significantly decreased by a dose of 7.5 mg/kg body weight and virtually abolished by a dose of 10 mg/kg body weight. It is suggested that daunomycin may interfere with the latent period of the immune response.
Get full access to this article
View all access options for this article.
References
1.
BernardJ., PaulR., BoironM., JacquillatC., and MaralL.: Rubidomycin.A new agent against cancer. p. 42. Springer-Verlag Ed., Berlin, 1969.
2.
CalendiE., Di MarcoA., ReggianiM., ScarpinatoB., and ValentiniL.: On the physico-chemical interaction between Daunomycin and nucleic acids.Biochim. biophys. Acta, 103: 25–49, 1965.
3.
CassinelliG., e OrezziP.: La daunomicina: un nuovo antibiotico ad attività citostatica, isolamento e proprietà.G. Microbiol., 11: 167–174, 1963.
4.
Di MarcoA., GaetaniM., DorigottiL., SoldatiM., e BelliniO.: Studi sperimentali sull'attività antineoplastica del nuovo antibiotico daunomicina.Tumori, 49: 203–215, 1963.
5.
Di MarcoA., GaetaniM., OrezziP., ScarpinatoB., SilvestriniR., SoldatiM., DasdiaT., and ValentiniL.: Daunomycin, a new antibiotic of the Rhodomycin group.Nature, 201: 706–707, 1964.
6.
HonigG. R., SmulsonM. E., and RabinovitzM.: A requirement of RNA synthesys for oxidation dependent biosynthesis in sarcoma 37 ascites-tumor cells.Biochim. biophys. Acta, 129: 576–584, 1966.
7.
JerneN., NordinA. A., and HenryC.: The agar plaque technique for recognizing antibody-producing cells.Conference on cell-bound antibodies. p. 109. AmosB., and KoprowskyH. Ed., Wistar Institute Press, Philadelphia, 1963.
8.
KerstenW., KerstenH., and SzybalskiW.: Physicochemical properties of complexes between deoxyribonucleic acid and antibiotics which affect ribonucleic acid synthesis (actinomycin, daunomycin, cinerubine, nogalomycin, chromomycin, mithramycin and olivomycin).Biochemistry, 5: 236–244, 1966.
9.
KoschelK., HartmannG., KerstenW., und KerstenH.: Die Wirkung des Chromomycins und einiger Anthracyclinantibiotica auf die DNA-abhängige Nucleinsäure-Synthese.Biochem. Z., 344: 76–86, 1966.
10.
RusconiA., and Di MarcoA.: Inhibition of nucleic acid synthesis by Daunomycin and its relationship to the uptake of the drug in HeLa cells.Cancer Res., 29: 1507–1511, 1969.
11.
SilvestriniR., e GaetaniM.: Azione della daunomicina sul metabolismo nucleico del tumore ascite di Ehrlich.Tumori, 49: 389–397, 1963.
12.
TanC., TasakaH., Kou-Ping-Yu, MurphyL., and KarnofskyD.: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.Cancer, 20: 333–353, 1967.
13.
VendittiJ. M., AbbottJ., Di MarcoA., and GoldinA.: Effectiveness of Daunomycin (NSC-82151) against experimental tumors.Cancer Chemother. Rep., 50: 659–665, 1966.
14.
WardD. C., ReichE., and GoldbergI. H.: Base specificity in the interaction of polynucleotides with antibiotic drugs.Science, 149: 1259–1263, 1965.
15.
Whang-PengJ., LeventhalB. G., AdamsonJ. W., and PerryS.: The effect of Daunomycin in human cells in vivo and in vitro.Cancer, 23: 113–121, 1969.
